| Symlin (pramlintide) / AstraZeneca |
NCT00108004: Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus |
|
|
| Completed | 3b | 400 | US | pramlintide acetate | AstraZeneca | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 06/05 | 06/05 | | |
NCT00042458: Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control |
|
|
| Completed | 3 | 296 | US | Pramlintide acetate, Placebo | AstraZeneca | Diabetes Mellitus, Type 1 | 03/03 | 03/03 | | |
NCT00107107: Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus |
|
|
| Completed | 3 | 190 | US | pramlintide acetate | AstraZeneca | Diabetes Mellitus, Type 1 | 06/05 | 06/05 | | |
| Completed | 3 | 30 | US | Pramlintide and glucagon | Baylor College of Medicine | Type 1 Diabetes | | 08/05 | | |
NCT00206297: The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes |
|
|
| Completed | 3 | 20 | US | Pramlintide | Baylor College of Medicine | Type 1 Diabetes | | 02/06 | | |
NCT00923715: Exenatide (Byetta) Versus Pramlintide (Symlin): Role in Post-Prandial Hyperglycemia |
|
|
| Enrolling by invitation | 3 | 63 | US | Insulin, Insulin and Exenatide, Insulin and Pramlintide | Baylor College of Medicine, Albert Einstein College of Medicine of Yeshiva University | Diabetes Mellitus, Type 1 | 12/11 | 05/12 | | |
